Hints and tips:
...Earlier this year, Solvay of Belgium announced a €3.4bn bid for French rival Rhodia....
...competition now means new funds can often make a high double-digit return in a couple of months from even the most mainstream deals, such as the €4.5bn ($5.8bn) takeover by Abbott Laboratories of the US of Solvay...
...MedImmune, which is now part of AstraZeneca, Baxter, CSL and Solvay are also being sent samples, as are smaller developers Microgen, Nobilon International, Omnivest Vaccines and Vivaldi....
...The acquisition of General Chemical from Harbinger Capital Partners will make the Indian conglomerate’s soda ash unit, Tata Chemicals, the world’s second-largest producer of the material behind Belgium’s Solvay...
...Solvay shed 2.2 per cent to €101.80 as hopes faded that it would start marketing the drug to diabetics....
...Solvay and Lundbeck were both hit by a delay to the European launch of Bifeprunox, their jointly-produced treatment for schizophrenia....
...Solvay climbed 2.3 per cent to €92 after the Belgian drug and chemicals group said it hoped to open a new research and development centre in Shanghai in the first quarter of next year....
International Edition